Galectin Therapeutics’ (GALT) Neutral Rating Reiterated at HC Wainwright

HC Wainwright restated their neutral rating on shares of Galectin Therapeutics (NASDAQ:GALT) in a research note published on Wednesday morning,Benzinga reports. HC Wainwright also issued estimates for Galectin Therapeutics’ FY2029 earnings at ($0.91) EPS.

Separately, StockNews.com cut Galectin Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, December 30th.

Galectin Therapeutics Price Performance

Shares of GALT stock opened at $1.32 on Wednesday. Galectin Therapeutics has a 1-year low of $0.73 and a 1-year high of $4.27. The firm has a market cap of $82.85 million, a PE ratio of -1.81 and a beta of 0.69. The company has a 50-day moving average of $1.46 and a two-hundred day moving average of $1.94.

Galectin Therapeutics (NASDAQ:GALT) last posted its quarterly earnings data on Monday, March 31st. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03). Sell-side analysts anticipate that Galectin Therapeutics will post -0.73 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. State Street Corp boosted its position in Galectin Therapeutics by 9.3% in the 3rd quarter. State Street Corp now owns 251,014 shares of the company’s stock valued at $690,000 after buying an additional 21,399 shares during the period. Kovitz Investment Group Partners LLC acquired a new stake in shares of Galectin Therapeutics in the third quarter valued at $117,000. Barclays PLC boosted its holdings in Galectin Therapeutics by 309.0% in the third quarter. Barclays PLC now owns 28,587 shares of the company’s stock valued at $79,000 after purchasing an additional 21,598 shares during the period. Geode Capital Management LLC boosted its holdings in Galectin Therapeutics by 2.5% in the third quarter. Geode Capital Management LLC now owns 862,542 shares of the company’s stock valued at $2,372,000 after purchasing an additional 20,817 shares during the period. Finally, Soltis Investment Advisors LLC acquired a new position in Galectin Therapeutics during the 3rd quarter worth $387,000. Institutional investors and hedge funds own 11.68% of the company’s stock.

About Galectin Therapeutics

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.